Intravenous immunoglobulin and Alzheimer’s disease: what now?

Comparison of Intravenous Immunoglobulins for Naturally Occurring Autoantibodies against Amyloid-β

(2017) Karthikeyan Balakrishnan et al.   JOURNAL OF ALZHEIMERS DISEASE

Intravenous immunoglobulin products contain specific antibodies to recombinant human tau protein

(2013) Lynnae M. Smith et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

(2013) Richard Dodel et al.   LANCET NEUROLOGY

Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?

(2013) Jens Moreth et al.   Immunity & Ageing

Immunotherapy for Alzheimer’s disease: from anti-β-amyloid to tau-based immunization strategies

(2012) Francesco Panza et al.   Immunotherapy

The Advantage of Specific Intravenous Immunoglobulin (sIVIG) on Regular IVIG: Experience of the Last Decade

(2012) Nina Svetlicky et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer’s disease

(2012) Lakshman Puli et al.   Journal of Neuroinflammation

Does vascular pathology contribute to Alzheimer changes?

(2012) Raj N. Kalaria et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Vascular risk factors in Alzheimer's disease — Preliminary report

(2012) E. Stefanova et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Analysis and Functional Consequences of Increased Fab-Sialylation of Intravenous Immunoglobulin (IVIG) after Lectin Fractionation

(2012) Fabian Käsermann et al.   PLoS One

In vitroandin vivoproperties differ among liquid intravenous immunoglobulin preparations

(2012) F. Dhainaut et al.   VOX SANGUINIS

Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barré syndrome

(2011) Jeffrey L Winters et al.   BMC HEALTH SERVICES RESEARCH

Passive Immunization with Anti-Tau Antibodies in Two Transgenic Models

(2011) Xiyun Chai et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain

(2011) Allal Boutajangout et al.   JOURNAL OF NEUROCHEMISTRY

Naturally Occurring Autoantibodies against  -Amyloid: Investigating Their Role in Transgenic Animal and In Vitro Models of Alzheimer's Disease

(2011) R. Dodel et al.   JOURNAL OF NEUROSCIENCE

Thromboembolic complications of intravenous immunoglobulin therapy in patients with neuropathy: A two-year study

(2011) Yusuf A. Rajabally et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Specific antibodies to soluble alpha-synuclein conformations in intravenous immunoglobulin preparations

(2010) L. M. Patrias et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease

(2010) Johanna Magga et al.   Journal of Neuroinflammation

Aβ-directed Single-chain Antibody Delivery Via a Serotype-1 AAV Vector Improves Learning Behavior and Pathology in Alzheimer's Disease Mice

(2010) Deborah A Ryan et al.   MOLECULAR THERAPY

Intravenous immunoglobulin preparation type: Association with outcomes for patients with acute Kawasaki disease

(2010) Cedric Manlhiot et al.   PEDIATRIC ALLERGY AND IMMUNOLOGY

Effect of IVIG administration on complement activation and HLA antibody levels

(2010) Takafumi Machimoto et al.   TRANSPLANT INTERNATIONAL

Antibody concentrations to Aβ1–42 monomer and soluble oligomers in untreated and antibody–antigen-dissociated intravenous immunoglobulin preparations

(2009) Andrea C. Klaver et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Therapeutic activities of intravenous immunoglobulins in multiple sclerosis involve modulation of chemokine expression

(2009) Nadine Pigard et al.   JOURNAL OF NEUROIMMUNOLOGY

IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders

(2009) H. Fillit et al.   NEUROLOGY

Anti-Inflammatory Actions of Intravenous Immunoglobulin

(2008) Falk Nimmerjahn et al.   Annual Review of Immunology

Natural human antibodies to amyloid beta peptide

(2008) Paul Szabo et al.   AUTOIMMUNITY REVIEWS

Human Plasma Contains Cross-Reactive Aβ Conformer-Specific IgG Antibodies†

(2008) Brian O’Nuallain et al.   BIOCHEMISTRY

Intravenous immunoglobulins induce CD32-mediated platelet aggregationin vitro

(2008) A. Pollreisz et al.   BRITISH JOURNAL OF DERMATOLOGY

The Role of the Cell Surface LRP and Soluble LRP in Blood-Brain Barrier Aβ Clearance in Alzheimers Disease

(2008) R. Deane et al.   CURRENT PHARMACEUTICAL DESIGN

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease

(2008) Norman R. Relkin et al.   NEUROBIOLOGY OF AGING

Epidemiology of chronic kidney disease: Results from a population of older adults in Germany

(2008) Qiu-Li Zhang et al.   PREVENTIVE MEDICINE

Identification of a receptor required for the anti-inflammatory activity of IVIG

(2008) R. M. Anthony et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Recapitulation of IVIG Anti-Inflammatory Activity with a Recombinant IgG Fc

(2008) R. M. Anthony et al.   SCIENCE

The Mechanisms of Action of Intravenous Immunoglobulin and Polyclonal Anti-D Immunoglobulin in the Amelioration of Immune Thrombocytopenic Purpura: What Do We Really Know?

(2008) Andrew R. Crow et al.   TRANSFUSION MEDICINE REVIEWS

Variation of anti-Fas antibodies in different lots of intravenous immunoglobulin

(2008) B. M. Reipert et al.   VOX SANGUINIS